 in leadership positions. I think he covered it well when he said the equivalent of if you've seen one shortage, you've seen one shortage. There are many that are demand-driven, and he talked a little bit about some of those, the GLP-1s most notably, like Wegovy and Ozempic. But there's a lot of supply side, and that is due first and foremost, as the FDA has said in its own drug shortages report, due to manufacturing issues and heavily dominated within the generic space.